Literature DB >> 17024101

Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban.

H Fechner1, L Suckau, J Kurreck, I Sipo, X Wang, S Pinkert, S Loschen, J Rekittke, S Weger, D Dekkers, R Vetter, V A Erdmann, H-P Schultheiss, M Paul, J Lamers, W Poller.   

Abstract

Impaired function of the phospholamban (PLB)-regulated sarcoplasmic reticulum Ca(2+) pump (SERCA2a) contributes to cardiac dysfunction in heart failure (HF). PLB downregulation may increase SERCA2a activity and improve cardiac function. Small interfering (si)RNAs mediate efficient gene silencing by RNA interference (RNAi). However, their use for in vivo gene therapy is limited by siRNA instability in plasma and tissues, and by low siRNA transfer rates into target cells. To address these problems, we developed an adenoviral vector (AdV) transcribing short hairpin (sh)RNAs against rat PLB and evaluated its potential to silence the PLB gene and to modulate SERCA2a-mediated Ca(2+) sequestration in primary neonatal rat cardiomyocytes (PNCMs). Over a period of 13 days, vector transduction resulted in stable > 99.9% ablation of PLB-mRNA at a multiplicity of infection of 100. PLB protein gradually decreased until day 7 (7+/-2% left), whereas SERCA, Na(+)/Ca(2+) exchanger (NCX1), calsequestrin and troponin I protein remained unchanged. PLB silencing was associated with a marked increase in ATP-dependent oxalate-supported Ca(2+) uptake at 0.34 microM of free Ca(2+), and rapid loss of responsiveness to protein kinase A-dependent stimulation of Ca(2+) uptake was maintained until day 7. In summary, these results indicate that AdV-derived PLB-shRNA mediates highly efficient, specific and stable PLB gene silencing and modulation of active Ca(2+) sequestration in PNCMs. The availability of the new vector now enables employment of RNAi for the treatment of HF in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17024101     DOI: 10.1038/sj.gt.3302872

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  16 in total

Review 1.  Antisense makes sense in engineered regenerative medicine.

Authors:  Yongchang Yao; Chunming Wang; Rohan R Varshney; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

2.  Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.

Authors:  Naa-Adjeley D Ablorh; David D Thomas
Journal:  Biophys Rev       Date:  2015-01-21

Review 3.  EGR-mediated control of STIM expression and function.

Authors:  Christina K Go; Scott Gross; Robert Hooper; Jonathan Soboloff
Journal:  Cell Calcium       Date:  2018-12-06       Impact factor: 6.817

4.  Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.

Authors:  Sandra Pinkert; Karin Klingel; Vanessa Lindig; Andrea Dörner; Heinz Zeichhardt; O Brad Spiller; Henry Fechner
Journal:  J Virol       Date:  2011-10-05       Impact factor: 5.103

5.  Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines.

Authors:  Lawrence T Bish; Meg M Sleeper; Caryn Reynolds; Jeffrey Gazzara; Elanor Withnall; Gretchen E Singletary; George Buchlis; Daniel Hui; Katherine A High; Guangping Gao; James M Wilson; H Lee Sweeney
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

6.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

Review 7.  Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure.

Authors:  Wolfgang Poller; Roger Hajjar; Heinz-Peter Schultheiss; Henry Fechner
Journal:  Cardiovasc Res       Date:  2010-02-22       Impact factor: 10.787

8.  Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging.

Authors:  Katrin Wittköpper; Larissa Fabritz; Stefan Neef; Katharina R Ort; Clemens Grefe; Bernhard Unsöld; Paulus Kirchhof; Lars S Maier; Gerd Hasenfuss; Dobromir Dobrev; Thomas Eschenhagen; Ali El-Armouche
Journal:  J Clin Invest       Date:  2010-01-11       Impact factor: 14.808

9.  Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers.

Authors:  Brian D Lowes; Ronald Zolty; Simon F Shakar; Andreas Brieke; Norman Gray; Michael Reed; Mihail Calalb; Wayne Minobe; JoAnn Lindenfeld; Eugene E Wolfel; Mark Geraci; Michael R Bristow; Joseph Cleveland
Journal:  J Heart Lung Transplant       Date:  2007-11       Impact factor: 10.247

10.  Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy.

Authors:  Henry Fechner; Isaac Sipo; Dirk Westermann; Sandra Pinkert; Xiaomin Wang; Lennart Suckau; Jens Kurreck; Heinz Zeichhardt; Oliver Müller; Roland Vetter; Volker Erdmann; Carsten Tschope; Wolfgang Poller
Journal:  J Mol Med (Berl)       Date:  2008-06-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.